Genitourinary Cancer

PV QA 1 - Poster Viewing Q&A 1

SU_26_2263 - Free PSA ratio as a predictor of adverse outcomes after curative-intent external beam radiation therapy for prostate cancer: a novel application of an "old" biomarker

Sunday, October 21
1:15 PM - 2:45 PM
Location: Innovation Hub, Exhibit Hall 3

Free PSA ratio as a predictor of adverse outcomes after curative-intent external beam radiation therapy for prostate cancer: a novel application of an "old" biomarker
H. Goldberg1, R. Glicksman2,3, N. E. Fleshner1, D. T. S. Woon1, Z. Klaassen1, T. Chandrasekar1, J. O. H. Caceres1, N. S. Salgado2,3, M. X. Qu2,3, F. Y. Moraes2,3, G. S. Kulkarni1, R. J. Hamilton1, P. Chung2,3, C. N. Catton2,3, A. Finelli1, and A. Berlin2,3; 1Department of Surgical Oncology, Division of Urology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada, 2Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, 3Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada

Purpose/Objective(s): Most serum PSA circulates in complex with protease inhibitors, but 5%-45% does it as enzymatically inactive free PSA (fPSA). PSA produced from prostate cancer (PC) cells appears to escape proteolytic processing, resulting in a greater fraction of complexed PSA (e.g. lower fPSA). Based on this, fPSA ratio is commonly used as an adjunct marker to improve the accuracy of PSA for screening. Within the PSA range 4-10 ng/mL, a fPSA ratio higher than 0.15 correlates with lower risk of harbouring PC. Nonetheless, post treatment fPSA is rarely quantified, and its prognostic value after radical external beam radiotherapy (EBRT) remains unexplored.

Materials/Methods: Institutional databases were queried to identify intermediate- and high-risk PC patients treated between 1992 and 2012 with EBRT, who had at least one ascertainment of fPSA during follow-up. Patients were stratified according to a fPSA cut-off of 0.15. Multivariable Cox regression models were performed to determine the correlation of post-EBRT fPSA and clinical outcomes.

Results: A total of 355 patients were identified. Of these, 262 (73.8%) and 93 (26.2%) had a fPSA ratio<0.15 and ≥0.15, respectively. Mean age, pre-treatment total PSA, and clinical T-category were similar in both groups. However, patients with a fPSA ratio ≥0.15 had a higher biopsy Gleason score (GS), NCCN risk group, and were more often treated with combined EBRT and androgen deprivation therapy (ADT). Mean follow-up time was similar in both groups (109.5 months vs. 111.9 months, p=0.725). Biochemical recurrence (BCR) rate were similar in both groups (77.6% vs. 80.5%, p=0.58), as expected from the Institutional lab policy of ascertaining fPSA when total PSA is in the 4-10ng/mL range and therefore BCR most likely already established. However, the metastasis and castrate resistant prostate cancer (CRPC) rates were higher in the fPSA ≥0.15 group (41.3% vs. 21.5%, p<0.001, and 67.4% vs. 37.5%, p=0.002, respectively). Multivariable models demonstrated that along with higher GS, a fPSA fraction>=0.15 conferred a statistically significantly higher hazard ratio (HR) for metastasis (HR 2.027, 95% CI 1.28-3.21, p=0.003), and CRPC (HR 3.066, 95% CI 1.565-6.004, p=0.01).

Conclusion: This study suggests that a fPSA ratio>=0.15 in the setting of post curative-intent EBRT denotes a more aggressive disease, reflected in higher rates of metastasis and CRPC. Our findings suggest a reversal in the significance of fPSA ratio in the post treatment state, and a potential novel role for this widely available and low-cost biomarker.

Author Disclosure: H. Goldberg: None. R. Glicksman: None. N.E. Fleshner: None. D.T. Woon: None. T. Chandrasekar: None. M. Qu: None. P. Chung: Research Grant; Sanofi. C.N. Catton: Research Grant; AbbVie Corporation. Advisory Board; AbbVie Corporation, Bayer Corporation, Estellas Corporation. Chair of Sarcoma Services Committe; CancerCare Ontario. A. Finelli: None.

Send Email for Rachel Glicksman


Assets

SU_26_2263 - Free PSA ratio as a predictor of adverse outcomes after curative-intent external beam radiation therapy for prostate cancer: a novel application of an "old" biomarker



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Free PSA ratio as a predictor of adverse outcomes after curative-intent external beam radiation therapy for prostate cancer: a novel application of an "old" biomarker